I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety
7.1.2026 10:00:00 EET | Business Wire | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor.
Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works.
This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commercial relationships with customers that must continue to invest heavily in maintaining and upgrading ageing roads, transport networks, and utility infrastructure. Demand is further reinforced by increasingly stringent safety and regulatory requirements for infrastructure works, raising the need for professional traffic management and safety services. Ramudden’s scale, specialized equipment, and deep technical experience enable it to deliver these services efficiently and generate strong returns.
Ramudden Global was created by Triton, together with founders and management, and formed through the acquisition of several platform companies beginning with Ramudden (Sweden) in December 2017, followed by AVS (Germany) in January 2018, Chevron (UK) and Fero (Belgium and Netherlands) in April of the same year. Following the acquisitions, the companies had a joint annual turnover of approximately EUR 280 million (USD $308 million). The individual companies were merged into a single group in 2020, expanding from one of the European market leaders into the world’s first pan-Atlantic platform, with the addition of Canada-based RSG International in 2024 and US-based Curtin in 2025.
Today, around two-thirds of the company’s operations are in Europe, with the remaining third split between Canada and the United States. The joint group turnover as of January 2026 is more than EUR 1 billion (USD $1.2 billion)1. I Squared’s acquisition will support Ramudden Global’s next phase of growth across North America and Europe.
Mohamed El Gazzar, Senior Partner, I Squared Capital commented: “Ramudden Global is one of the clear market leaders across its key geographies providing a critical service that helps thousands of customers meet strict and regulatory-driven safety standards. For I Squared, Ramudden is well positioned to benefit from predictable, long-term spending and a high level of recurring demand. We’re excited to work with Ramudden to support its continued growth and evolution from a European leader to a world-class global infrastructure safety platform.”
Peder Prahl, Founder and CEO of Triton said: “All of us at Triton would like to thank the platform founders, group management and the company’s skilled employees for their hard work and contributions during our ownership and for their continuous efforts in building the future of Ramudden. We are glad to have been able to support the board and management to execute the long-term vision for Ramudden Global by setting the strategy and overseeing the creation of a recognized European and global champion in a fragmented and overlooked industry.”
Morten Finslo, CEO Ramudden Global said: “Ramudden Global is today well positioned to continue expanding our footprint, investing in innovation and digital solutions, and strengthening our ability to deliver safe, reliable traffic management services for our customers across Europe and North America. We are excited to partner with I Squared Capital on this transaction; they bring deep infrastructure expertise and a long-term investment approach that aligns well with our growth ambitions.”
The transaction is expected to close in the first half of 2026 subject to customary regulatory approvals and closing conditions. Financial terms were not disclosed.
About I Squared Capital
I Squared Capital is a leading global infrastructure investor managing $50 billion in assets. We build and scale essential infrastructure businesses that deliver critical services to millions of people worldwide. The I Squared portfolio includes over 90 companies operating in more than 70 countries and spanning sectors such as energy, utilities, digital infrastructure, transport, environmental and social infrastructure. Headquartered in Miami, its team of over 300 professionals is based across offices in Abu Dhabi, London, Munich, New Delhi, São Paulo, Singapore, Sydney and Taipei. Learn more at www.isquaredcapital.com.
About Ramudden Global
Ramudden Global is one of the leading international providers of traffic management (TTM) services for critical infrastructure projects. It delivers end-to-end solutions that include project planning, asset provision, on-site set-up, project monitoring, and final completion.
With a team of over 5,000 employees, Ramudden is committed to delivering the highest quality in every project and advancing our mission: to get people home safely every day.
At present, Ramudden operates in 13 countries throughout Europe and North America, supporting a customer base of more than 10,000.
About Triton
Founded in 1997 and owned by its partners, Triton is a leading European mid-market sector-specialist investor. Triton focuses on investing in businesses that provide mission critical goods and services in its three core sectors of Business Services, Industrial Tech, and Healthcare.
Triton has over 150 investment professionals and value creation experts across eleven offices and invests through three complementary “All Weather” strategies: Mid-Market Private Equity, Smaller Mid-Cap Private Equity, and Opportunistic Credit.
Disclaimers
This document does not constitute advice or a recommendation or offer to sell or a solicitation to deal in any security or financial product. It is provided for information purposes only. Investing involves risk, loss of principal is possible. Specific investments described herein do not represent all investment decisions made by ISQ. The reader should not assume that investment decisions identified and discussed were or will be profitable. Specific investment advice references provided herein are for illustrative purposes only and are not necessarily representative of investments that will be made in the future.
1 | Past performance is no guarantee of future results |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260107644696/en/
Contacts
Media:
I Squared Capital
Sofie Brewis / Shelly Hagan
info@isquaredcapital.com
Triton
media@triton-partners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom